The first patient has been enrolled in a Phase 1 trial by the NHLBI that's evaluating fostamatinib as a treatment for sickle ...

triggering classic responses of platelet activation, aggregation, adhesion, and secretion. Platelet activation also results in protein synthetic activities, release of thrombo-inflammatory modulators, ...

A still growing number of studies are highlighting potentially important differences in the pathways mainly involved in platelet aggregation in physiological hemostasis vs. pathological thrombosis.

At the JPM Healthcare conference last month, Idorsia's chief executive, Jean-Paul Clozel, presented phase 2 data with platelet aggregation inhibitor selatogrel, saying it has the potential to ...

Learning about your genetics and ancestry is easier than ever. All you need to do is choose from the many DNA ancestry tests available online, receive your kit and send back the required DNA samples.

Oxide nanoparticles, particularly iron oxide, ceria and silica nanoparticles, hold significant promise for biomedical applications owing to their unique magnetic, catalytic and porous properties ...

After more than 70 years of effective clinical use, heparin remains the most common anticoagulant in use and one of the most commonly prescribed drugs to hospitalized patients. However, the ...

Meloxicam is an enolcarboxamide with preferential COX-2 activity. Studies conducted on experimental models and human tissues indicate that meloxicam is a more potent inhibitor of COX-2 than COX-1 ...